Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

AbbVie Inc

ABBV
Current price
160.45 USD -1.69 USD (-1.04%)
Last closed 162.55 USD
Sector Healthcare
Industry Drug Manufacturers - General
Exchange NYSE
Capitalization 287 042 174 976 USD
Yield for 12 month +9.28 %
1Y
3Y
5Y
10Y
15Y
ABBV
21.11.2021 - 28.11.2021

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois. Address: 1 North Waukegan Road, North Chicago, IL, United States, 60064-6400

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

183.2 USD

P/E ratio

48.378

Dividend Yield

3.81 %

Current Year

+54 318 000 000 USD

Last Year

+58 054 000 000 USD

Current Quarter

+12 310 000 000 USD

Last Quarter

+14 301 000 000 USD

Current Year

+45 538 000 000 USD

Last Year

+40 640 000 000 USD

Current Quarter

+8 228 000 000 USD

Last Quarter

+11 915 000 000 USD

Key Figures ABBV

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA 25 660 999 680 USD
Operating Margin TTM 24.6 %
PE Ratio 48.378
Return On Assets TTM 7.51 %
PEG Ratio 0.4488
Return On Equity TTM 56.24 %
Wall Street Target Price 183.2 USD
Revenue TTM 54 402 998 272 USD
Book Value 4.54 USD
Revenue Per Share TTM 30.78 USD
Dividend Share 6.06 USD
Quarterly Revenue Growth YOY 0.7 %
Dividend Yield 3.81 %
Gross Profit TTM 41 527 000 000 USD
Earnings Share 3.36 USD
Diluted Eps TTM 3.36 USD
Most Recent Quarter I 2024
Quarterly Earnings Growth YOY 496.4 %
Profit Margin 11.02 %

Dividend Analytics ABBV

Champion - 10+ consecutive years of dividend increases

Dividend growth over 5 years

65 %

Continuous growth

10 years

Payout Ratio 5 years average

126 %

Dividend History ABBV

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate 6.2
Ex Dividend Date 12.04.2024
Forward Annual Dividend Yield 3.81 %
Last Split Factor
Payout Ratio 55.29 %
Last Split Date
Dividend Date 15.05.2024

Stock Valuation ABBV

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE 48.378
Forward PE 14.5773
Enterprise Value Revenue 6.1473
Price Sales TTM 5.29
Enterprise Value EBITDA 19.445
Price Book MRQ 27.7356

Financials ABBV

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators ABBV

For 52 weeks

125.85 USD 181.2 USD
50 Day MA 172.43 USD
Shares Short Prior Month 14 691 308
200 Day MA 157.67 USD
Short Ratio 2.11
Shares Short 13 536 080
Short Percent 0.77 %

Dynamics of changes in the value of assets

Stocks


MSFT

MSFT

409.34 USD Microsoft Corporation -4.27 (-1.03%)
Detailed analytics

ETF funds


S

SX7EEX

14.33 EUR iShares EURO STOXX Banks 30-15 UCITS ETF (DE) +0.03 (+0.22%)
Detailed analytics

Metals


Gold

2318.97 USD Gold -3.58 (-0.15%)
Detailed analytics